ScholarLens Back to search
2014•The Practical Journal of CancerRequires access

Clinical Study of Radiofrequency Ablation Combined with Transcatheter Hepatic Arterial Chemoembolization for Hepatic Carcinoma

Ying Zhang

Open publisher page 1 citations

Abstract

Objective To evaluate the clinical value of radiofrequency ablation( RFA) combined with transcatheter hepatic arterial chemoembolization( TACE) on hepatic carcinoma. Methods 61 patients with primary liver cancer were divided into two groups: 34 cases were treated with TACE alone and 27 cases were treated with TACE combined with RFA. To evaluate the efficacy with DSA、CT、ultrasound and serum alpha-fetoprotein( AFP) after treatment. Results The tumor efficiency、relapse rate and 1-year survival rates of TACE group were 52. 9% 、38. 2% 、48. 4% respectively,and those of the TACE + RFA combination group were 85. 2% 、59. 3% and 79. 4% respectively,and there was statistical differences between the two groups( P 0. 05). Conclusion Compared with TACE,TACE + RFA is effective for advanced liver cancer. It is an effective method for the treatment of advanced hepatocellular carcinoma,and has high clinical value.

About this research paper

What this paper is about

Objective To evaluate the clinical value of radiofrequency ablation( RFA) combined with transcatheter hepatic arterial chemoembolization( TACE) on hepatic carcinoma. Methods 61 patients with primary liver cancer were divided into two groups: 34 cases were treated with TACE alone and 27 cases were treated with TACE combined with RFA. To evaluate the efficacy with DSA、CT、ultrasound and serum alpha-fetoprotein( AFP) after treatment. Results The tumor efficiency、relapse rate and 1-year survival rates of TACE group were 52. 9% 、38. 2% 、48. 4% respectively,and those of the TACE + RFA combination group were 85. 2% 、59. 3% and 79. 4% respectively,and there was statistical differences between the two groups( P 0. 05). Conclusion Compared with TACE,TACE + RFA is effective for advanced liver cancer. It is an effective method for the treatment of advanced hepatocellular carcinoma,and has high clinical value.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the clinical value of radiofrequency ablation( RFA) combined with transcatheter hepatic arterial chemoembolization( TACE) on hepatic carcinoma. Methods 61 patients with primary liver cancer were divided into two groups: 34 cases were treated with TACE alone and 27 cases were treated with TACE combined with RFA. To evaluate the efficacy with DSA、CT、ultrasound and serum alpha-fetoprotein( AFP) after treatment. Results The tumor efficiency、relapse rate and 1-year survival rates of TACE group were 52. 9% 、38. 2% 、48. 4% respectively,and those of the TACE + RFA combination group were 85. 2% 、59. 3% and 79. 4% respectively,and there was statistical differences between the two groups( P 0. 05). Conclusion Compared with TACE,TACE + RFA is effective for advanced liver cancer. It is an effective method for the treatment of advanced hepatocellular carcinoma,and has high clinical value.

Key concepts: Medicine, Transcatheter arterial chemoembolization, Radiofrequency ablation, Hepatocellular carcinoma, Liver cancer, Hepatic carcinoma, Gastroenterology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Study of Radiofrequency Ablation Combined with Transcatheter Hepatic Arterial Chemoembolization for Hepatic Carcinoma — Research Paper | ScholarLens